98.13 0.00 (0.00%)
After hours: 4:27PM EDT
|Bid||97.71 x 800|
|Ask||98.97 x 1200|
|Day's Range||97.84 - 98.76|
|52 Week Range||58.59 - 98.76|
|Beta (3Y Monthly)||1.82|
|PE Ratio (TTM)||14.95|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Leoplus USA is developing Duet, a device and app which aims to support communications between people with MS and their care partners to help improve patients' disease management outcomes. "We know communication within families affected by multiple sclerosis can be challenging. Duet is an innovative way to create connections with those you love," said Tim Coetzee, Ph.D., Chief Advocacy, Services and Research Officer at the National Multiple Sclerosis Society, who served as chair of the judging panel.
Celgene Corporation (CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with relapsing forms of multiple sclerosis (RMS) in the United States. The European Medicines Agency (EMA) also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) in the European Union.
Bristol-Myers Squibb Company (BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with Celgene Corporation (CELG). The company is evolving key aspects of its R&D and Commercialization structure to drive the continued growth of a highly successful marketed portfolio, maximize the six near-term launch opportunities and deliver the value of the combined pipeline, all guided by its continued mission of serving patients with serious disease.
Data show the potential of investigational anti-CD19 chimeric antigen receptor T-cell therapy in patients with previously treated blood cancers, including those with high-risk dise
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. The FDA has granted Priority Review to this BLA for the evaluation of the beta-thalassemia indication and set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 4, 2019.
Celgene Corporation (CELG) announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib in patients with myelofibrosis previously treated with ruxolitinib. This updated analysis of fedratinib employed intent-to-treat (ITT) principles and utilized a narrower definition of ruxolitinib relapsed, refractory, or intolerant patients. Results were shared in a poster presentation today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Celgene Corporation (CELG) today announced the first clinical results evaluating iberdomide (CC-220) in combination with dexamethasone in patients with relapsed and refractory multiple myeloma from the ongoing phase 1/2 CC-220-MM-001 study during an oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The results included preliminary safety and efficacy data from the ongoing multicenter, open-label, dose-escalation study, which aims to determine the maximum tolerated dose and the recommended phase 2 dose of iberdomide in combination with dexamethasone. Iberdomide is Celgene’s proprietary cereblon E3 ligase modulator (CELMoD®) compound with enhanced tumoricidal and immune stimulatory effects demonstrated in preclinical studies.
Approval marks the first chemotherapy-free combination regimen for patients who have relapsed or did not respond to previous treatment
Celgene Corporation (CELG) and the Multiple Sclerosis Association of America (MSAA) today announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that provides new perspective on multiple sclerosis (MS). The campaign aims to educate about the critical role the brain plays in the disease and what people living with MS can do to keep their brain as healthy as possible, for as long as possible. To bring this new perspective on MS closer to the community, the campaign will host engaging, educational events in various cities.
The European Commission has approved two of Celgene’s IMiD®-based combination regimens:
Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple myeloma
Celgene plans to submit sNDA by end of 2019
Finalist patient entrepreneurs recognized for potential of innovations in multiple sclerosis (MS) NEW YORK , May 10, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform ...
Celgene Corporation (CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss versus first-line treatment, Avonex® (interferon beta-1a), in adults with relapsing multiple sclerosis (RMS) across all age groups, including patients ages 18 to 25. The analysis will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, May 4-10, 2019.
Celgene Corporation (CELG) and bluebird bio, Inc. (BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies’ lead investigational BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy candidate for patients with relapsed and refractory multiple myeloma. The manuscript, “Anti-BCMA CAR T Cell Therapy bb2121 in Relapsed/Refractory Multiple Myeloma”, published in NEJM includes key safety and efficacy results from the dose escalation and first expansion cohort, including a minimum of six months follow up on all subjects. Patients in the study were heavily pre-treated, with a median of seven prior multiple myeloma treatment regimens (range, 3 to 23), which included prior treatment with immunomodulatory drugs, proteasome inhibitors and daratumumab in the majority of patients.
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. Luspatercept is an investigational erythroid maturation agent that regulates late-stage red blood cell maturation.
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
Celgene Corporation (CELG) today announced that its stockholders have voted to approve the company’s proposed combination with Bristol-Myers Squibb Company (BMY). Approximately 98% of the votes cast, and over 70% of the shares outstanding and entitled to vote, voted in favor of the transaction at the special meeting. “On behalf of the Celgene Board of Directors, I would like to thank our stockholders for their overwhelming support of this transaction,” said Mark Alles, Chairman and Chief Executive Officer of Celgene.
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.
The CHMP adopted two positive opinions recommending European Commission approval of:
Celgene Corporation (CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials.
Bristol-Myers Squibb Company’s (BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (CELG). In addition to its March 19 investor presentation, the Company today also made available on Bristol-Myers Squibb’s website at www.bestofbiopharma.com and later today will file with the Securities and Exchange Commission (SEC) an investor presentation providing an overview of Bristol-Myers Squibb’s ability to derive value from Celgene’s pipeline and a Fact Sheet providing additional detail on key benefits of the transaction.
TECENTRIQ® in Combination with ABRAXANE® receives accelerated approval for people with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer